DATE: August 8, 2018

FROM: Jeffrey S. Murray M.D., M.P.H.
Division of Antiviral Products

SUBJECT: Deputy Director Memorandum for NDA 22343
Efavirenz, Lamivudine, and Tenofovir disoproxil fumarate (DF)
Tablets 600 mg/300 mg/300 mg

APPLICANT: Aurobindo Pharma Ltd. (Pharma)

TO: HFD-530/Division files

I. Background and Clinical Findings
The availability of a wide range of safe and effective antiretroviral drug products is hoped to facilitate a wider distribution of anti-HIV drugs to better meet the demands of the global HIV/AIDS pandemic. On Oct. 2006, FDA published a guidance entitled “Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment of HIV”. The guidance encourages sponsors to develop various drug product versions of previously approved antiretroviral drugs and encourages sponsors to submit new drug applications for these products to FDA for review. Although many antiretroviral drug product versions of previously approved antiretroviral drugs cannot be currently approved or marketed in the US because of existing patents and exclusivity, FDA can review these products for quality, safety and efficacy and potentially grant a tentative approval. When patents and exclusivities expire, applicants may seek final approval. The President’s Emergency Plan for AIDS Relief will consider procurement of products reviewed by FDA that have been granted approval or tentative approval. Such products may be distributed outside the US, depending on regulatory requirements in other countries.

On May 25, 2012, Aurobindo submitted this 505(b)(2) NDA for a fixed dose tablet containing three widely used antiretroviral drugs, lamivudine, tenofovir disoproxil DF and efavirenz for tentative approval under the PEPFAR program. The application was tentatively approved on June 26, 2013. On February 16, 2018, Aurobindo submitted a class 2 resubmission requesting final approval and marketing in the United States.
The safety and efficacy of this triple FDC is supported by previously conducted adequate and well-controlled trials of the individually approved components and a previous clinical trial with this specific triple combination. The safety of the drugs contained in these tablets has also been well characterized in the individual drug development programs of the individual innovator products and with the extensive postmarketing experience of the innovator drugs. This FDC is a complete HIV regimen in treatment naïve patients, and allows for once daily dosing with a single tablet.

II. Summary of the Application
Refer to the Office of Pharmaceutical Quality (OPQ) memo prepared by team lead Stephen Miller, Ph.D. Dr. Miller summarized changes included in the resubmission and recommends final approval from a product quality perspective.

Please refer to the clinical pharmacology review prepared by Assad Noory, at the time of tentative approval, for details of the review of the bioequivalence study. In brief, Mylan’s fixed dose tablets containing lamivudine 300 mg, tenofovir 300 mg, and efavirenz 600 mg were bioequivalent to the U.S. approved reference formulations of the individual products, Epivir® tablets (lamivudine) 150 mg GlaxoSmithKline, Research Triangle Park, NC 27709), Viread® tablets (tenofovir) 300 mg (Gilead Sciences), and Sustiva® tablets (efavirenz) 600 mg (manufactured by Bristol Myers Squib, USA) when the three single entity tablets were given together in a single dose to healthy volunteers under fasting conditions. The tablets are recommended to be taken on an empty stomach. An inspection of the clinical site for the bioequivalence study was acceptable. The analytical inspections were based on previous acceptable inspections.

Please refer to the labeling review prepared by David Araojo, PharmD. The package insert and patient package insert provide similar information as the individual products and is deemed adequate to allow for safe and effective use of this FDC.

III. Recommendation
Aurobindo’s Efavirenz, Lamivudine, and Tenofovir DF Tablets 600 mg/300 mg/300 mg, should be approved for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.

Jeffrey S. Murray M.D., M.P.H.
Deputy, Division of Antiviral Products
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JEFFREY S MURRAY
08/14/2018